Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

421. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.

Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. 2407957 1990 04 12 1990 04 12 2013 11 21 0028-4793 322 12 1990 Mar 22 The New England journal of medicine N. Engl. J. Med. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. 802-9 Although fluoride increases bone mass, the newly formed bone may have reduced strength. To assess the effect of fluoride treatment on the fracture rate in osteoporosis, we conducted (...) a four-year prospective clinical trial in 202 postmenopausal women with osteoporosis and vertebral fractures who were randomly assigned to receive sodium fluoride (75 mg per day) or placebo. All received a calcium supplement (1500 mg per day). Sixty-six women in the fluoride group and 69 women in the placebo group completed the trial. As compared with the placebo group, the treatment group had increases in median bone mineral density of 35 percent (P less than 0.0001) in the lumbar spine

NEJM1990

422. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. 2109197 1990 05 24 1990 05 24 2013 11 21 0028-4793 322 18 1990 May 03 The New England journal of medicine N. Engl. J. Med. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. 1265-71 Progressive bone loss in osteoporosis results from bone resorption in excess of bone formation. We conducted a double (...) -blind study in 66 women with postmenopausal osteoporosis of therapy with etidronate, a diphosphonate compound that reduces bone resorption by inhibiting osteoclastic activity. The patients were randomly assigned in equal numbers to receive oral etidronate (400 mg per day) or placebo for 2 weeks, followed by a 13-week period in which no drugs were given. This sequence was repeated 10 times, for a total of 150 weeks. Daily oral supplementation with calcium and vitamin D was given throughout the study

NEJM1990

423. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).

Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). 2892989 1988 02 29 1988 02 29 2015 06 16 0140-6736 1 8578 1988 Jan 23 Lancet (London, England) Lancet Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). 143-6 In a prospective, randomised, placebo-controlled trial comparing the effect of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) (150 mg/day) plus calcium (1 g/day (...) , University of Auckland, New Zealand. King A R AR Alexander C J CJ Ibbertson H K HK eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't England Lancet 2985213R 0140-6736 0 Diphosphonates 0 Glucocorticoids OYY3447OMC pamidronate SY7Q814VUP Calcium AIM IM Calcium therapeutic use Clinical Trials as Topic Diphosphonates therapeutic use Female Glucocorticoids adverse effects therapeutic use Humans Male Menopause Middle Aged Osteoporosis chemically

Lancet1988

424. Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis.

Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. 2899773 1988 09 08 1988 09 08 2015 06 16 0140-6736 2 8607 1988 Aug 13 Lancet (London, England) Lancet Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. 361-5 The risk-benefit ratio of combined fluoride-calcium therapy in primary vertebral osteoporosis was examined prospectively in patients with at least one vertebral fracture. 257 patients were randomised to receive sodium (...) and over Ankle Calcium administration & dosage therapeutic use Clinical Trials as Topic Drug Administration Schedule Drug Evaluation Drug Therapy, Combination Female Follow-Up Studies Foot Fractures, Spontaneous drug therapy prevention & control Gastrointestinal Diseases chemically induced Humans Male Middle Aged Osteoporosis drug therapy prevention & control Pain chemically induced Random Allocation Risk Factors Sodium Fluoride administration & dosage adverse effects therapeutic use Spinal Diseases

Lancet1988

425. Prevention of spinal osteoporosis in oophorectomised women.

Prevention of spinal osteoporosis in oophorectomised women. 6107766 1981 01 29 1981 01 29 2016 11 23 0140-6736 2 8205 1980 Nov 29 Lancet (London, England) Lancet Prevention of spinal osteoporosis in oophorectomised women. 1151-4 100 women who had taken part in a prospective controlled trial of oestrogen therapy for prevention of post-oophorectomy bone loss were reviewed after a median follow-up period of nine years. A significant reduction in height occurred among the placebo-treated group (...) imaging Osteoporosis prevention & control Radiography Spinal Diseases prevention & control Spine diagnostic imaging 1980 11 29 1980 11 29 0 1 1980 11 29 0 0 ppublish 6107766 S0140-6736(80)92592-1

Lancet1980